Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

Ann Oncol. 2019 Nov 1;30(11):1848. doi: 10.1093/annonc/mdz221.
No abstract available

Publication types

  • Published Erratum